Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 984-988

  Inoue, Satoko ^b   Nakase, Hiroshi ^a,b   Matsuura, Minoru ^b   Ueno, Satoru ^b   Uza, Norimitsu ^b   Kitamura, Hiroshi ^b   Mikami, Sakae ^b   Tamaki, Hiroyuki ^b   Kasahara, Katsuhiro ^b   Chiba, Tsutomu ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Antibiotics; Clarithromycin; Crohn's disease; Immunomodulator; Luminal bacteria

Indexed keywords

AZATHIOPRINE; CLARITHROMYCIN; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ABDOMINAL DISCOMFORT; ABDOMINAL FULLNESS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CROHN DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; ILEUM; JAPANESE; MALE; MONOTHERAPY; OPEN STUDY; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34347387623     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04533.x     Document Type: Article

References (25)

1. Bamias G, Marini M, Moskaluk CA et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J. Immunol. 2002 169 : 5308 14.
2. Greenberg GR. Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm. Bowel Dis. 2004 10 : 318 20.
3. Wild GE. The role of antibiotics in the management of Crohn's disease. Inflamm. Bowel Dis. 2004 10 : 321 3.
4. Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991 32 : 1071 5.
5. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 2002 8 : 10 15.
6. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. J. Gastroenterol. 1998 12 : 53 6.
7. Ishikawa T, Okamura S, Oshimoto H, Kobayashi R, Mori M. Metronidazole plus ciprofloxacin therapy for active Crohn's disease. Intern. Med. 2003 42 : 318 21.
8. Ives TJ, Schwab UE, Ward ES, Butts JD, Hall IH. Disposition and functions of clarithromycin in human THP-1 monocytes during stimulated and unstimulated conditions. Res. Commun. Mol. Pathol. Pharmacol. 2001 110 : 183 208.
9. Xu G, Fujita J, Negayama K et al. Effect of macrolide antibiotics on macrophage functions. Microbiol. Immunol. 1996 40 : 473 9.
10. Ichiyama T, Nishikawa M, Yoshitomi T et al. Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother. 2001 45 : 44 7.
11. Kikuchi T, Hagiwara K, Honda Y et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappaB transcription factors. J. Antimicrob. Chemother. 2002 49 : 745 55.
12. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp. Clin. Res. 1989 15 : 527 33.
13. Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob. Agents Chemother. 1996 40 : 1366 70.
14. Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. Two-year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother. 1997 39 : 393 400.
15. Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy: approaching a cure? Dig. Liver Dis. 2002 34 : 29 38.
16. Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig. Liver Dis. 2002 34 : 22 8.
17. Goodgame RW, Kimball K, Akram S et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment. Pharmacol. Ther. 2001 15 : 1861 6.
18. Rubin PH, Chapman ML, Scherl E, Sachar DB, Stamaty C, Present DH. Clarithromycin in active Crohn's disease: preliminary results of open label pilot study. Gastroenterology 1996 110 : A1005.
19. Douglass A, Cann PA, Bramble MG. An open pilot study of antimicrobial therapy in patients with unresponsive Crohn's disease. Gut 2000 46 (Suppl. II A11.
20. Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment. Pharmacol. Ther. 2000 14 : 801 6.
21. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol. Suppl. 1996 525 : 73 8.
22. Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 2004 351 : 2069 79.
23. Summers RW, Switz DM, Sessions JT et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979 77 : 847 69.
24. Malchow H, Ewe K, Brandes JW et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984 86 : 249 66.
25. Steinhart AH, Faegan BG, Wong CJ et al. Combined budesonide and antibiotic therapy for active Crohn's disease. Gastroenterology 2002 123 : 33 40.